Buradasınız

Anasayfa » Content

Kronik Böbrek Hastalığında Tanı ve Tedavi ile Kardiyovasküler Hastalık ve Risk Faktörlerinin Değerlendirilmesi

Diagnosis and Treatment in Chronic Kidney Disease and Evalution of Cardiovascular Disease and Associated Risk Factors

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 2008

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Today, chronic kidney disease (CKD) is a world-wide public health problem. Losing kidney function and occurance of cardiovas¬cular disease (CVD) are inevitablely the main clinical outcomes. Increasing evidence suggested that the adverse outcomes of CKD can be prevented or delayed through early detection and treatment. CKD and hypertension are often present together and hypertension is both a cause and a complication of CKD and is a risk factor for progression of kidney disease and for CVD. The goals of antihypertensive therapy in CKD are to lower blood pressure, reduce the risk of CVD, slow progression of CKD and prevent the complications of decreased GFR. A clinical action plan should be developed for each patient, based on the stage of CKD and follow-up intervals for monitoring the patients should be determined by clinical condition.
Bookmark/Search this post with
Abstract (Original Language): 
Günümüzde kronik böbrek hastalığı (KBH) dünya genelinde yaygın bir halk sağlığı problemidir. Böbrek fonksiyonlarının kaybedilmesi ve kardiyovasküler hastalık (KVH) gelişimi kaçınılmaz olarak meydana gelen ana klinik sonuçlardır. Artan kanıtlar KBH'nın kötü sonuçlarının erken tanı ve tedaviyle önlenebileceğini veya geciktirilebileceğini ileri sürmektedir. KBH ve hipertansiyon (HT) sıklıkla birliktedir ve HT, KBH'nın hem nedeni hem de komplikasyonu olup KBH'nın ilerlemesi ve KVH açısından bir risk faktörüdür. KBH'da an-tihipertansif tedavinin amacı kan basıncını düşürmek, KVH riskini azaltmak, KBH'nın ilerlemesini yavaşlatmak ve düşük GFR'nin komplikasyonlarını önlemektir. KBH'nın evresi temelinde her hasta için bir klinik eylem planı geliştirilmelidir ve hastaların takip edilme¬si için takip aralığı klinik duruma göre belirlenmelidir.
FULL TEXT (PDF): 
PDF icon arastrmx_172977_17_pp_1-9.pdf
  • 1
1-9
  • Turkish

REFERENCES

References: 

1. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 2002;39(suppl 2):S1-S266.
2. US Renal Data System. USRDS 2000 Annual Report, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Bethesda, MD, 2000.
3. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 2003;289:2560-2572.
4. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B,
Hamm HL, McCullough PA, Kasiske BL, Kelepouris E, Klag
MJ, Parfrey PS, Pfeffer M, Raij L, Spinosa DJ, Wilson PW:
Kidney disease as a risk factor for development of cardiovascular disease. A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology and Epidemiology and Prevention. Circulation 2003;108:2154-2169.
5. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, Gans RO, Janssen WM, Grobbee DE, de Jong PE: Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population.
Circulation 2002;106:1777-1782.
6. Manjunath G, Tighiouart H, Ibrahim H, MacLeod B, Salem
DN, Griffith JL, Coresh J, Levey AS, Sarnak MJ: Level of
kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol
2003;41:47-55.
7. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW,
Hogg RJ, Perrone RD, Lau J, Eknoyan G: National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med
2003;139:137-147.
8. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS: Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis
2003;41:1-12.
9. Jacobs DR Jr, Murtaugh MA, Steffes M, Yu X, Roseman J, Goetz FC: Gender- and race-specific determination of albumin excretion rate using albumin-to-creatinine ratio in single, untimed urine specimens: The Coronary Artery Risk Development in Young Adults Study. Am J Epidemiol
2002;155:1114-1119.
10. Buckalew VM Jr, Berg RL, Wang SR, Porush JG, Rauch S,
Schulman G: Prevalence of hypertension in 1,795 subjects with chronic renal disease: the modification of diet in renal disease study baseline cohort. Modification of Diet in Renal
Disease Study Group. Am J Kidney Dis 1996;28:811-821.
11. Sarnak MJ, Levey AS: Cardiovascular disease and chronic
8
Türk
Nefroloj
i Diyaliz ve Transplantasyon Dergisi /Official Journal of the Turkish Society of Nephrology
Kronik Böbrek Hastalığında Tanı ve Tedavi ile Kardiyovasküler Hastalık ve Risk Faktörlerinin Değerlendirilmesi £
renal disease: A new paradigm. Am J Kidney Dis
2000;35(suppl 1):S117-S131.
12. Parfrey PS, Foley RN: The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol
1999;10:1606-1615.
13. McCullough PA: Why is chronic kidney disease the "spoiler" for cardiovascular outcomes? J Am Coll Cardiol 2003;41:725-728.
14. Stehouwer CD, Gall MA, Twisk JW, Knudsen E, Emeis JJ,
Parving HH: Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: Progressive, interrelated, and independently associated with risk of death. Diabetes 2002;51:1157-1165.
15. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, Halle JP, Young J, Rashkow A, Joyce C, Nawaz S, Yusuf S: Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic
individuals. JAMA 2001;286:421-426.
16. Grimm RH Jr, Svendsen KH, Kasiske B, Keane WF, Wahi MM: Proteinuria is a risk factor for mortality over 10 years of follow-up. MRFIT Research Group. Multiple Risk Factor
Intervention Trial. Kidney Int Suppl 1997;63:S10-S14.
17. Culleton BF, Larson MG, Parfrey PS, Kannel WB, Levy D:
Proteinuria as a risk factor for cardiovascular disease and mortality in older people: A prospective study. Am J Med
2000;109:1-8.
18. Matts JP, Karnegis JN, Campos CT, Fitch LL, Johnson JW,
Buchwald H: Serum creatinine as an independent predictor of coronary heart disease mortality in normotensive survivors of myocardial infarction. POSCH Group. J Fam Pract
1993;36:497-503.
19. Walsh CR, O'Donnell CJ, Camargo CA Jr, Giugliano RP, Lloyd-Jones DM: Elevated serum creatinine is associated with a 1-year mortality after acute myocardial infarction. Am Heart
J 2002;144:1003-1011.
20. Beattie JN, Soman SS, Sandberg KR, Yee J, Borzak S, Garg M,
McCullough PA: Determinants of mortality after myocardial infarction in patients with advanced renal dysfunction. Am J
Kidney Dis 2001;37:1191-1200.
21. Wison S, Foo K, Cunningham J, Cooper J, Deaner A, Knight C, Ranjadayalan K, Timmis AD: Renal function and risk stratification in acute coronary syndromes. Am J Cardiol
2003;91:1051-1054.
22. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S: Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: The HOPE randomized trial [see comments]. Ann Intern Med 2001;134:629-636.
23. Ruilope LM, Salvetti A, Jamerson K, Hansson L, Warnold I, Wedel H, Zanchetti A: Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J Am Soc
Nephrol 2001;12:218-225.
24. Schillaci G, Reboldi G, Verdecchia P: High-normal serum creatinine concentration is a predictor of cardiovascular risk
in essential hypertension. Arch Intern Med 2001;161:886-891.
25. Garg AX, Clark WF, Haynes RB, House AA: Moderate renal
insufficiency and the risk of cardiovascular mortality: Results
from the NHANES I. Kidney Int 2002;61:1486-1494.
26. Hunsicker LG, Adler S, Caggiula A, England BK, Greene T, Kusek JW, Rogers NL, Teschan PE: Predictors of the progression of renal disease in the Modification of Diet in
Renal Disease Study. Kidney Int 1997;51:1908-1919.
27. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med
2003;348:383-393.
28. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
(ALLHAT). JAMA 2002;288:2981-2997.
29. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
30. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann
Intern Med 1999;130:461-470.
31. Eknoyan G, Hostetter T, Bakris GL, Hebert L, Levey AS, Parving HH, Steffes MW, Toto R: Proteinuria and other markers of chronic kidney disease: A position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases
(NIDDK). Am J Kidney Dis 2003;42:617-622.
32. Kinchen KS, Sadler J, Fink N, Brookmeyer R, Klag MJ, Levey AS, Powe NR: The timing of specialist evaluation in chronic kidney disease and mortality. Ann Intern Med 2002;137:479-486.
33. Avorn J, Bohn RL, Levy E, Levin R, Owen WF Jr, Winkelmayer WC, Glynn RJ: Nephrologist care and mortality in patients with chronic renal insufficiency. Arch Intern Med
2002;162:2002-2006.
34. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet
2002;359:995-1003.
35. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med
2001;345:851-860.
36. Jackson TW, Bakris G, Greene T, et al: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. Results from the
AASK Trial. JAMA 2002;288:2421-2431.

Thank you for copying data from http://www.arastirmax.com